Sumy C. Daeufer she/her

Principal

E sumy.daeufer@faberlawgroup.com

P (781) 795 4706

Sumy's background in the life sciences make her particularly adept at guiding clients through complex transactions that drive value in all phases of drug development from R&D to commercial product licensing.

As lead transactional counsel she helps clients navigate and negotiate strategic product research, development and commercialization transactions, technology and product licensing, academic research collaborations and licensing and commercial product manufacturing and supply chain transactions. Sumy also supervises Faber's contract support team.

BAR ADMISSIONS

Massachusetts
New York

EDUCATION

Yale Law School, J.D.
Yale University, B.A., Summa Cum Laude

faber

Experience

Associate General Counsel, Discovery and Development Group

Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Company Limited)

- Manager of the Discovery and Development Group within the legal department
- Member of the committee responsible for managing Millennium's product pipeline
- Business team member for the company's marketed products
- Lead in-house attorney for the development and commercialization alliance for Millennium's first oncology drug

Counsel to Parke-Davis Pharmaceutical Division in North America and South Africa

Sidley Austin LLP – Business Transactions Group

- Focused on secured financing, M&A transactions, and initial public offerings

Client Work

- Hovione's exclusive out-license agreement with Ji Xing Pharmaceuticals for global rights to a pre-clinical ophthalmology program
- Alnylam's research collaboration with Novartis to discover RNAi therapeutics to promote the regrowth of functional liver cells
- Alnylam's participation in the Medicines Manufacturing Innovation Centre Grand Challenge 3 (GC3) consortium with Exactmer, CPI, AstraZeneca and Novartis
- Omega Therapeutic's development and option agreement with Acuitas Therapeutics
- Alnylam's research and development collaboration with Vir to develop RNAi therapeutics for COVID-19 and other coronaviruses
- Alnylam's disease education and promotion agreement with Ironwood for Alnylam's givosiran
- Alnylam's research and development collaboration with Regeneron for new treatments of nonalcoholic steatohepatitis (NASH) and other liver diseases
- Alnylam's research and development collaboration with Vir Biotechnology to develop RNAi therapeutics for chronic hepatitis B virus and other infectious diseases
- ImmunoGen's sale and license to Debiopharm of its Phase 2 anti-CD37 non-Hodgkin lymphoma (NHL) antibody-drug conjugate (ADC) product program
- AB Biosciences' exclusive license to Shire of its recombinant immunoglobulin product
- EpimAb's research and development collaboration with Kymab for bispecific therapeutic antibodies
- Biogen's research collaboration with Arsia Therapeutics to develop subcutaneous formulations of Biogen's hemophilia products
- Alnylam's expansion of its strategic alliance and broad crosslicensing arrangement with Isis Pharmaceuticals (now Ionis Pharmaceuticals)
- Biogen's drug discovery collaboration with Array BioPharma for kinase inhibitors for inflammatory disease

- Atara Biotherapeutics' exclusive license of clinical-stage T-cell therapy technology from Memorial Sloan Kettering Cancer Center
- Biogen's in-license and transfer of an antibody discovery technology platform from Adimab
- Alnylam's license and collaboration agreement with The Medicines Company for siRNA molecules targeting PCSK9
- Biogen's drug discovery collaboration with Amicus in Parkinson's
- Alnylam's exclusive global alliance with the The Medicines Company for the development and commercialization of Alnylam's ALN-PCS RNAi therapeutic program for hypercholesterolemia
- Alnylam's strategic collaboration with Ascletis to develop an RNAi therapeutic for liver cancer in China
- Phenex's research collaboration and license agreement with Janssen for autoimmune and chronic inflammatory disorders